SOMAPACITAN (Sogroya®)
Clinical Indication
For treating severe growth hormone deficiency in people 3 to 17 years.
Comments
In line with NICE TA 1066
Date of classification
July 2025
Red
Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.